



22 July 2015

Entitlements Issue Completed

Optiscan is pleased to announce completion of the fully underwritten 1:15 entitlements issue announced on 15 June 2015.

The issue raised approximately \$690,000, which together with the short term \$500,000 debt facility also announced in June, has provided the Company with important funding support.

As reported in June, Optiscan is focussed on the near term release of the second generation animal imaging system, CellLIVE, which is scheduled for release in September at the World Molecular Imaging Conference in Hawaii.

Optiscan is also continuing its discussions with Carl Zeiss over the final stages of the project to deliver its neurosurgery confocal imaging system. These discussions charter a range of commercial issues relating to supply, regulatory responsibilities and service in relation to the product. At this time, we remain on track to report the outcomes of these discussions by the end of September.

About Optiscan

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Peter Delaney, Director of Technology
Tel (613) 9538 3391
GusH@optiscan.com

Bruce Andrew, CFO
Tel (613) 9538 3398
brucea@optiscan.com